ES2120025T3 - Derivados de xantina utilizados como antagonistas de receptores de adenosina a1. - Google Patents

Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.

Info

Publication number
ES2120025T3
ES2120025T3 ES94910661T ES94910661T ES2120025T3 ES 2120025 T3 ES2120025 T3 ES 2120025T3 ES 94910661 T ES94910661 T ES 94910661T ES 94910661 T ES94910661 T ES 94910661T ES 2120025 T3 ES2120025 T3 ES 2120025T3
Authority
ES
Spain
Prior art keywords
receptor antagonists
adenosine receptor
derivatives used
pct
xanthine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910661T
Other languages
English (en)
Spanish (es)
Inventor
Janice M Hitchcock
Stephen M Sorenson
Mark W Dudley
Norton P Peet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2120025T3 publication Critical patent/ES2120025T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES94910661T 1993-02-26 1994-01-27 Derivados de xantina utilizados como antagonistas de receptores de adenosina a1. Expired - Lifetime ES2120025T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2350193A 1993-02-26 1993-02-26

Publications (1)

Publication Number Publication Date
ES2120025T3 true ES2120025T3 (es) 1998-10-16

Family

ID=21815459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910661T Expired - Lifetime ES2120025T3 (es) 1993-02-26 1994-01-27 Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.

Country Status (19)

Country Link
US (1) US5840729A (enExample)
EP (1) EP0686155B1 (enExample)
JP (1) JPH08512281A (enExample)
KR (1) KR100315898B1 (enExample)
CN (1) CN1041418C (enExample)
AT (1) ATE169019T1 (enExample)
AU (1) AU680241B2 (enExample)
CA (1) CA2155130C (enExample)
DE (1) DE69412073T2 (enExample)
DK (1) DK0686155T3 (enExample)
ES (1) ES2120025T3 (enExample)
HU (1) HUT72677A (enExample)
IL (1) IL108750A (enExample)
MX (1) MX9401406A (enExample)
NO (1) NO311920B1 (enExample)
NZ (1) NZ262984A (enExample)
TW (1) TW261532B (enExample)
WO (1) WO1994019349A1 (enExample)
ZA (1) ZA941176B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
BR0215202A (pt) 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
AU2003239472A1 (en) * 2002-05-15 2003-12-02 Genzyme Corporation Synthesis of benzonitriles and benzimidates
WO2004086047A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
JPWO2005056016A1 (ja) * 2003-12-09 2007-07-05 協和醗酵工業株式会社 高次脳機能障害の予防および/または治療剤
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0455150A (ja) * 1990-06-22 1992-02-21 Takata Kk 助手席用エアバッグ装置
US5087827A (en) * 1991-02-11 1992-02-11 Tektronix, Inc. Variable voltage transition circuit
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
ZA941176B (en) 1994-09-20
US5840729A (en) 1998-11-24
HU9502495D0 (en) 1995-10-30
IL108750A (en) 2000-09-28
DK0686155T3 (da) 1999-02-01
DE69412073D1 (de) 1998-09-03
MX9401406A (es) 1994-08-31
HUT72677A (en) 1996-05-28
NO311920B1 (no) 2002-02-18
CN1118599A (zh) 1996-03-13
DE69412073T2 (de) 1999-02-18
CN1041418C (zh) 1998-12-30
JPH08512281A (ja) 1996-12-24
ATE169019T1 (de) 1998-08-15
NZ262984A (en) 1997-05-26
NO953353L (no) 1995-08-25
IL108750A0 (en) 1994-05-30
CA2155130A1 (en) 1994-09-01
EP0686155A1 (en) 1995-12-13
KR100315898B1 (ko) 2002-02-28
AU6296894A (en) 1994-09-14
WO1994019349A1 (en) 1994-09-01
CA2155130C (en) 1994-09-01
AU680241B2 (en) 1997-07-24
EP0686155B1 (en) 1998-07-29
NO953353D0 (no) 1995-08-25
TW261532B (enExample) 1995-11-01

Similar Documents

Publication Publication Date Title
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
DE69611377D1 (de) 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor
ES2121193T3 (es) Derivados de bencimidazoles.
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
DE69327536D1 (de) Fibrinogenrezeptor-antagonisten
ATE141792T1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ES2134929T3 (es) Derivados de pirrolo-piridina como ligandos para receptores de dopamina.
DK0686155T3 (da) Xanthinderivater som adenosin A1-receptor-antagonister
PT1019426E (pt) Agonistas e antagonistas do receptor de adenosina a1
ATE113056T1 (de) Künstliche rezeptor-analoge.
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
ES2074332T3 (es) Derivados de polihidroxiciclopentano, su preparacion y su uso terapeutico.
ES2143224T3 (es) Derivados naftamida de 3-beta-amino azabiciclo octano o nonano, como agentes antipsicoticos.
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
NO974687L (no) Kondenserte <beta>-carboliner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686155

Country of ref document: ES